30 August 2021
EFPIA Japan

Propositions to Improve Scientific Validity and Transparency:
EFPIA Japan Publishes Latest Position Papers on
Cost-Effectiveness Assessment for Medicines
TOKYO – 30 August 2021 – EFPIA Japan today published its latest position papers on the costeffectiveness assessment system for medicines in Japan. The association’s up-to-date policy
recommendations are now available at efpia.jp. In 2015, before the introduction of the costeffectiveness assessment system (CEA), EFPIA Japan put forth its policy recommendations"EFPIA Viewpoint: Health Technology Assessment Application in Select Markets and Implications
for Japan”. Since then, upon the introduction and development of the CEA system, EFPIA Japan
has been clarifying its views and continuously calling for improvements to the system. In thelatest publication, EFPIA Japan identifies operational issues of the system and challenges in thescientific validity of the assessments. To address the challenges that have become apparent inthe course of the CEA processes after the full implementation of the system in 2019, EFPIA
Japan is also in this paper proposing solutions to address those issues.
1.

EFPIA Japan’s Basic Position on Cost-Effectiveness Assessment in Japan “ForImproving Scientific Validity and Transparency”
From a policy viewpoint, the paper identifies operational issues in the system andproposes solutions for better assessment of diverse values of medicines.

2.

EFPIA Japan’s Basic Position on Cost-Effectiveness Assessment in Japan “Issuesin Scientific Validity”
From a scientific viewpoint, the paper identifies technical issues in cost-effectivenessanalysis and assessment and proposes solutions for better assessment of diverse valuesof medicines.

EFPIA Japan as a policy partner continues to have dialogues with multiple stakeholders toestablish a drug pricing system where diverse values of medicines are properly reflected.

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
Tel: +81-3- 6417-2032
Fax: +81-3- 6685-4870

About EFPIA Japan (http://efpia.jp/)
Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceuticalcompanies operating in Japan. In 2020, combined sales from the member companies accounted
for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to“Contribute to healthcare and patients in Japan through the early introduction of innovative
medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in orderto improve Japanese healthcare for all.
About EFPIA (European Federation of Pharmaceutical Industries and Associations)(http://www.efpia.eu)
EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents thepharmaceutical industry operating in Europe. Through its direct membership of 36 national
associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies
committed to researching, developing and bringing new medicines to improve health and qualityof life around the world.
Contact:
Yuko Kidoguchi
EFPIA Japan Messaging & Communications Committee
1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268
Bayer Holding Ltd.
Tel: 03-6266-7757
Email: yuko.kidoguchi@bayer.com

EFPIA Japan
ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan
Tel: +81-3- 6417-2032
Fax: +81-3- 6685-4870